-
YD Bio signs merger MOU with EG BioMed for cancer diagnostics platform
-
YD Bio outlines 2026 clinical roadmap for eye treatments
-
YD Bio plans California operations center for U.S. expansion
-
YD Bio expands blood cancer testing to 44 US states
-
YD Bio enters U.S. eye care market with FDA-cleared contact lenses
-
YD Bio completes merger with SPAC, begins trading on NASDAQ

